Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2805801 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL2803264 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL14606164 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL28915215 | 0.98 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL28889985 | 0.98 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL28889927 | 0.98 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL30507677 | 0.98 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL28915206 | 0.98 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL30507665 | 0.98 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL30507684 | 0.95 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| CN-115322383-A | Polytelluroxane and preparation method thereof | 清华大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-108711636-B | Combined electrolyte type dual-ion rocking chair type secondary battery and preparation method thereof | 南京大学 | 2020-01-14 | — | — | CN | disclosed |
| US-20070185353-A1 | Method for producing alkylene glycol diethers | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185353-A1 | Method for producing alkylene glycol diethers | ABHD6, FAAH2, FAAH | MEN1 1392/4885KMT2A 2782/4885TSHR 1946/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3277/4885KMT2A 4465/4885TSHR 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.